This is why continuity writers would be helpful

This is why continuity writers would be helpful


4-9-18 update: "Grant Applications

One grant application has been filed with the National Institutes of Health (NIH) and two additional are planned with The National Science Foundation (NSF) and the Biomedical Advance Research and Development Authority (BARDA). Two of the applications are for funding for a pre-test for use with the N-Assay modified ELISA diagnostic and the BARDA application is for the use of the N-Assay for diagnostics of bio-threat agents.

As stated with the previous update from November, while there is strong competition for the grants, we believe the N-Assay and what it offers will be attractive to the grant evaluators."

this NIH grant app-the one you are looking for a date or whatever for- seemed to come out of the blue -nobody i've asked [havent asked NNLX] knows anything beyond what was stated
the NSF grant app was being processed as of the 11-27-17 update-" finalizing a grant application for $1,500,000.00 from the NSF" but we still do not know whether NNLX met the Dec 4 filing date or whether it was filed after the Dec 4 filing date for the then next round of grants

are the 2 additional NSF grant apps in addition to the NSF grant app referred to by the 11-27-17 update? -linguistics analysis cant answer that





Posted On: 04/09/2018 11:28:36 AM
Posted By: Kachingpdx1

[4-9-18] Update on Patents Offered for Sale and Licensing, Grant Applications

International Patent Offering

NanoLogix is pleased to provide this update on the ongoing work on the sale and/or licensing of the international issued FlatPack patents, and filed and in-process applications to the National Institutes of Health, The National Science Foundation and BARDA

We have had interest in the technology from companies in France, Spain, Turkey, Serbia, South Africa, and China. The interest varies from licensing arrangements, purchase, and through direct representation of our products.

The Company is currently in the process of raising $30,000 for the April payment of the international annuities for the issued FlatPack patents and pending applications in the following countries:

Issued: China, New Zealand, Chile, Mexico, South Africa, UK, Germany, Sweden, France, Spain, Italy, Switzerland, Serbia, Croatia, Turkey, Denmark, Ireland, Poland, and the Netherlands.

Pending: Brazil, Canada

Grant Applications

One grant application has been filed with the National Institutes of Health (NIH) and two additional are planned with The National Science Foundation (NSF) and the Biomedical Advance Research and Development Authority (BARDA). Two of the applications are for funding for a pre-test for use with the N-Assay modified ELISA diagnostic and the BARDA application is for the use of the N-Assay for diagnostics of bio-threat agents.

As stated with the previous update from November, while there is strong competition for the grants, we believe the N-Assay and what it offers will be attractive to the grant evaluators.

[11-27-17] Update on Patents Offered for Sale, UTI Presentation at CAOG, and NSF Grant Application-see post 4050 11-27-17

International Patent Offering

NanoLogix is pleased to provide this update on the ongoing work on the sale of the European and China issued FlatPack patents, the poster presentation dealing with the seriousness of the threat from Urinary Tract Infections (UTI) with the need for new rapid methods for diagnostics for UTI infections, and an in-process application to the National Science Foundation for a $1.5 million grant.

Since our first announcement of the offer of 12 July we have registered the patent in fourteen EU Patent Agreement signatory countries. That registration was completed by 7 September. At that time the official status of the FlatPack patent in Europe was recognized in those fourteen countries. Since 7 September, two of those countries, Sweden and Croatia, out of the fourteen countries in which the patent has been registered, have published that information in either their own national patent bulletins or the EU Patent bulletin. This publication step is generally required in order for a formal acceptance of the patent validity by interested parties. NanoLogix has no control over the timing of individual Country publication and hopes the remainder of the bulletin notifications could be completed by the end of the current quarter, fully realizing each country involved possesses its own separate bureaucracy and timetables. That stated, we are pleased to have had interest in the technology from companies in three European and adjacent countries.

For the offering of the FlatPack patent in China we are using the services of a broker in Asia and have as yet to receive notice of significant interest. China and Intellectual property rights have an interesting and varied history so we hope to find a large entity in China with the vision to recognize, acquire, and protect the granted China patent rights.

Central Association of Obstetricians and Gynecologists

Dr. Jonathan Faro, PhD, MD presented the following poster at the CAOG Annual Meeting in Scottsdale, Arizona:

179462903_NNLX-POSTER.jpg
NanoLogix and the authors are in agreement on the need for a rapid definitive diagnostic for UTI and the N-Assay and its soon to be developed screening pre-test are the needed tools to fill the projected need.

National Science Foundation Grant Application

NanoLogix, the Houston medical personnel involved in the N-Assay development and a professional grant writer are finalizing a grant application for $1,500,000.00 from the NSF for funding of both development of a screening ‘pre-test” to be used in conjunction with the N-Assay and also finalization for marketing of the N-Assay. Link to what is offered by the NSF can be found here:

NSF SBIR | NSF SBIR

While there is strong competition for the grants, we believe the N-Assay and what it offers will be attractive to the grant evaluators.